Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-63723283 (Cetrelimab) in Advanced Cancers
NCT02908906Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of cetrelimab in cancer, non-small cell lung cancer (NSCLC), melanoma and 6 more, sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity, Overall Response Rate and 1 more. Started Nov 2016; status: active, not recruiting.
02
Drugs
cetrelimab
03
Conditions
cancernon-small cell lung cancer (NSCLC)melanomarenal cell carcinoma (RCC)bladder cancer
Beyond the preview
Go deeper on NCT02908906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908906.